source
- Alnylam's experimental Huntington's therapy reduces mutant protein in early trialAlnylam Pharmaceuticals reported early data from a small study of its gene‑silencing drug for Huntington's disease. The investigational agent, brezosiran, was administered at several dose levels.…
- Bristol Myers Squibb identifies cause of safety signal in lupus CAR‑T trialBristol Myers Squibb's cell therapy division is confronting ongoing safety challenges with its autoimmune CAR‑T program. The company says it has pinpointed the underlying cause of the safety signa…